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Histopathological studies revealed that progressive neuropathies including Alzheimer,
and Prion diseases among others, include accumulations of misfolded proteins
intracellularly, extracellularly, or both. Experimental evidence suggests that among
the accumulated misfolded proteins, small soluble oligomeric conformers represent
the most neurotoxic species. Concomitant phenomena shared by different protein
misfolding diseases includes alterations in phosphorylation-based signaling pathways
synaptic dysfunction, and axonal pathology, but mechanisms linking these pathogenic
features to aggregated neuropathogenic proteins remain unknown. Relevant to this
issue, results from recent work revealed inhibition of fast axonal transport (AT) as a
novel toxic effect elicited by oligomeric forms of amyloid beta and cellular prion protein
PrPC, signature pathological proteins associated with Alzheimer and Prion diseases,
respectively. Interestingly, the toxic effect of these oligomers was fully prevented by
pharmacological inhibitors of casein kinase 2 (CK2), a remarkable discovery with
major implications for the development of pharmacological target-driven therapeutic
intervention for Alzheimer and Prion diseases.
Keywords: fast axonal transport, kinesin-1, casein kinase 2, signaling, synaptic dysfuction, protein misfolding,
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INTRODUCTION
Adult-onset misfolding diseases are among the most challenging disorders faced by modern
molecular medicine. A pathogenic feature common to these diseases includes the accumulation of
aggregated proteinaceous entities. By mid 20th century, it became clear that protein aggregates were
the culprit of misfolding diseases, including Alzheimer’s (AD) and prion diseases (PrDs) (Hardy
and Selkoe, 2002; Colby and Prusiner, 2011). More recently, the “amyloid cascade hypothesis”
was proposed, suggesting that a cascade of pathological events associated with extracellular
accumulation of amyloid precursor protein (APP) fragments underlies AD (Hardy and Higgins,
1992). This hypothesis was later extended to other misfolding diseases, leading to a modified
hypothesis that included the notion that smaller, oligomeric intraneuronal aggregates may play a
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more relevant pathological role in AD and PrDs, (Takahashi
et al., 2002; Forloni et al., 2016; Cline et al., 2018; Ono,
2018). As these disorders associated with small soluble
aggregates (oligomers ranging from 4 to 200 kDa), the term
“oligomeropathies” was coined to emphasize this notion (Forloni
et al., 2016). Still, after many decades of intense research,
mechanisms linking oligomeric protein aggregates to disease
pathogenesis remain elusive.
Synaptic disfunction and axonal pathology are common early
pathological features shared by neurons affected in protein
misfolding diseases (Selkoe, 2002; Senatore et al., 2013; Chiesa,
2015; Soto and Pritzkow, 2018), suggesting that pathological
misfolded proteins, including amyloid beta (Aβ) and PrPC,
may alter cellular processes critical for synaptic and axonal
function. One such process involves fast axonal transport (AT)
a cellular process crucial for homeostatic maintenance of pre
and postsynaptic compartments underlying functional neuronal
connectivity (Ermolayev et al., 2009a,b; Pigino et al., 2009;
Zamponi et al., 2017). In this mini-review, we discuss how two
unrelated pathogenic proteins bearing oligomeric conformation,
amyloid beta (oAβ-42) and cellular prion protein (oPrPC), inhibit
AT by altering a common signaling pathways important for AT
regulation. Implications of these in the Conclusion section.
EARLY SYNAPTIC DYSFUNCTION AND
NEURITIC PATHOLOGY IN PROTEIN
MISFOLDING DISEASES
Decades of research revealed neuronal synaptic terminals as
primary targets in many protein misfolded diseases (Jeffrey et al.,
2000; Selkoe, 2002; Conforti et al., 2007; Siskova et al., 2009).
Accordingly, recent studies determined that abnormally folded
tau and oligomeric amyloid beta, hallmarks AD proteins, inhibit
synaptic transmission through a mechanism involving aberrant
activation of the proteins kinases GSK3β and CK2, respectively
(Moreno et al., 2009, 2016). Early synaptic dysfunction and
axonal pathology represent common pathological events to all
these disorders, preceding months or even years before any
signs of overt neuronal cell death (Moreno and Mallucci, 2010;
Adalbert and Coleman, 2013). Cumulative evidence indicates
that deficits in neuronal connectivity associated with synaptic
disfunction and axonal degeneration, rather than the loss of
specific population of vulnerable neurons, underlies the clinical
manifestation of each disease (Chiesa et al., 2005; Brady
and Morfini, 2010; Coleman, 2011). Accordingly, therapeutic
strategies based on preventing neuronal apoptosis failed to alter
the progression of clinical symptoms in different animal models
of protein misfolding diseases, including PrDs, amyotrophic
lateral sclerosis (ALS) and PD (Chiesa et al., 2005; Gould
et al., 2006; Waldmeier et al., 2006). Remarkably, eliminating
cellular prion protein on mice infected with prions that
normally develop the classic prion pathology and clinical signs
of neurodegeneration (Mallucci et al., 2007; White et al.,
2008) recovered synaptic dysfunction, which further prevented
neuronal loss (Moreno and Mallucci, 2010). Therefore, the
available information strongly suggests that preserving neuronal
connectivity may represent an effective therapeutic strategy
(Lingor et al., 2012). However, the development of such
approaches requires the knowledge of pathogenic mechanism
underlying loss of neuritic connectivity in all these unrelated
neurological disorders (Luo and O’Leary, 2005; Conforti et al.,
2007; Gerdts et al., 2016).
The development of mouse models for misfolding disorders
was a major breakthrough that allowed an evaluation of
hypothesis-driven disease mechanisms (Suter and Scherer,
2003). However, a major obstacle has been the scarcity of
appropriate experimental systems that allow a direct evaluation
of aggregation-dependent effects of neuropathogenic proteins.
Within this context, the isolated squid axoplasm and squid giant
synapse preparation represents unique experimental systems
(Song et al., 2016). Isolated squid giant axon is independent
of any nuclear or synaptic activity contributions, which cannot
be achieved when working with mammalian neurons either
in vitro or in vivo (Grant et al., 2006; Kanaan et al., 2012;
Song et al., 2016). One putative limitation for the squid giant
axon, as well as other invertebrate model such as Drosophila
melanogaster and Caenorhabditis elegans, could be the state
of conservation on regulatory mechanisms for AT between
mammalian and invertebrate neurons. In this regard, we and
others have shown that every specific axonal activity explored
in the squid Loligo pealeii is conserved from cephalopods to
humans. The Loligo pealeii was a pioneering animal model
that provided fundamental insights into nerve cell excitability
(Schwiening, 2012). Furthermore, it was instrumental for the
discovery of kinesin-1 (Brady, 1985; Vale et al., 1985) and its
regulatory mechanisms (Brady and Morfini, 2017), as well as the
determination of the specific molecular mechanisms involved in
synaptic transmission (Llinas et al., 1980).
OLIGOMERIC FORMS OF Aβ-42 AND
PRPC PROMOTE ABERRANT
ACTIVATION OF THE PROTEIN KINASES
GSK3β AND CK2
A common pathological feature displayed by many adult onset
aggregopathies is aberrant patterns of protein phosphorylation,
which indirectly reflects alterations in the activity of
phosphotransferases (Walaas and Greengard, 1991; Baskaran
and Velmurugan, 2018). Cytoskeletal components of the axonal
compartment, including the microtubule-associated protein
tau and neurofilaments, are the most widely reported neuronal
proteins aberrantly phosphorylated in AD and PrDs (Stoothoff
and Johnson, 2005; Holmgren et al., 2012; Rudrabhatla, 2014).
In the last two decades of pharmacological research working
with multiple cellular and animal models, it has become clear
that GSK3-β kinase plays a key role in AD and PrDs pathology
(Llorens-Martin et al., 2014). Significantly, GSK3β activity has
been shown to be abnormally activated by the AD associated
oligomeric Aβ-42 peptide (oAβ-42) and by PrP (Perez et al.,
2003; Pigino et al., 2009; Decker et al., 2010; Tang et al., 2012;
Simon et al., 2014). In addition, extracellular fibrillar Aβ-42 (fAβ)
and either extracellular or intracellular oAβ-42 were found to
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FIGURE 1 | Common molecular mechanism of fast axonal transport inhibition
shared by oPrPC and oAβ-42. Cellular and pharmacological data determined
that both oPrPC and oAβ-42 induced fast axonal transport inhibition. The
inhibitory mechanism was mediated by the activation of endogenous CK2 and
GSK3β that in turn phosphorylated KLCs. Phosphorylation of KLCs (letter P
on KLCs) promoted the detachment of conventional kinesin from its
transported vesicular cargoes. We and others have shown that CK2 can also
phosphorylate kinesin-1 heavy chains (KHCs) (letter P on KHCs). Based on
our previous results working with KHCs phosphorylation, we predict an
additional mechanism of fast axonal transport inhibition induced by CK2
phosphorylation on KHCs which in turn will promote a reduction of kinesin-1
association to microtubules (MTs).
activate CK2 both in vivo and in vitro (Chauhan et al., 1993;
De Felice et al., 2009; Pigino et al., 2009; Tang et al., 2012;
Ramser et al., 2013). Making this even more compelling, PrP
reportedly associates with and activates CK2 (Meggio et al.,
2000; Chen et al., 2008; Zamponi et al., 2017). Together these
experimental evidences strongly indicates that oAβ-42 and oPrP
promote activation of neuronal GSK3β and CK2 kinases (Pigino
et al., 2009; Zamponi et al., 2017), a discovery bearing major
implications for both AD and PrP pathogenesis.
Since most kinases have many different neuronal substrates,
they could potentially affect a wide variety of cellular processes,
including gene transcription (Whitmarsh, 2007; Thapar and
Denmon, 2013; Gao and Roux, 2015), cytoskeleton organization
(Rudrabhatla, 2014), protein degradation and mitochondrial
function, among others. However, the precise molecular events
linking these processes to synaptic dysfunction and axonal
pathology have yet to be discovered. On the other hand,
we do know AT is a process of utmost importance for
maintaining normal axonal and synaptic function (Gibbs et al.,
2015; Zamponi et al., 2017). In support, loss of function
mutations in specific subunits of kinesin-1 and cytoplasmic
dynein, major motor proteins responsible for the execution of
AT, cause neuropathologies featuring synaptic dysfunction and
axonal pathology early in the course of disease (Reid, 2003;
Brady and Morfini, 2010).
FAST AXONAL TRANSPORT
ALTERATIONS IN ALZHEIMER AND
PRION DISEASES
In the last decade, genetic evidences have shown that alterations
in kinesin and cytoplasmic dynein motor functions underlie
a group of neuropathies (Brady and Morfini, 2010, 2017).
Interestingly, all of these disorders display synaptic dysfunction
and l axonopathy, signature pathogenic events associated with
dying-back degeneration of neurons (Brady and Morfini, 2010).
Although these neuropathies are associated with functional
mutations in molecular motors, it became apparent that many
more adult onset aggregopathies present defects in AT, including
AD, and PrDs (Gibbs et al., 2015; Brady and Morfini, 2017;
Zamponi et al., 2017). However, AT failure in these neuropathies
was a result of alterations in phosphotransferase activities
that regulate kinesin and dynein motor functions, rather than
through mutation-based loss of motor activities (Brady and
Morfini, 2017). Our recent results showed that cellular PrP
can activate endogenous axonal CK2 activity and induce a
dramatic inhibit AT of various membrane-bound organelles
including synaptic vesicles and mitochondria (Zamponi et al.,
2017). Abnormally activated CK2 in turn phosphorylates light
chains subunits of kinesin-1, inducing a dissociation of this
motor protein with its transported cargoes (Figure 1). Consistent
with this molecular mechanism, inhibition of endogenous CK2
activity by specific pharmacological CK2 inhibitors prevented
oPrP-induced AT inhibition in both isolated squid axoplasm
and mammalian neurons (Zamponi et al., 2017). Remarkably,
we and others have shown previously the same mechanism
of AT inhibition induced by the AD related peptide oAβ-
42 (Pigino et al., 2009; Tang et al., 2012). These important
discoveries represent a message of hope for the development
of therapies to treat aggregopathies involving compromised
AT. In particular, these insights would be crucial for treating
disorders that are induced by aggregated misfolded proteins
capable of altering phosphotransferases important for regulating
AT, a vitally important neuronal process that sustain normal axon
functions and synaptic activities.
CONCLUSION
For many decades the research on pathological mechanisms
associated to adult onset neurological disorders such as AD
and other aggregopathies, was focused almost exclusively
on preventing neuronal cell death. The development of
animal models, specifically focusing on these devastating
diseases, has helped in the formulation of new hypothesis
driven pathological mechanisms. Many research programs
have developed effective ways of preserving neurons affected
in these animal models, however, little or no progress was
achieved in stopping or slowing the progression of these
diseases. Indeed, cardinal research programs aimed to genetically
prove the direct involvement of apoptosis, a pathological
component of AD, PD, PrD, and ALS, determined that
although apoptosis plays an important role in these diseases,
preserving affected neurons did not prevent the clinical
symptoms or synaptic dysfunction and loss (Chiesa et al., 2005;
Gould et al., 2006).
The discovery that functional mutations in kinesin-1 and
cytoplasmic dynein, the main molecular motors responsible for
neuronal AT, suffice to promote dying back neuropathies was
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a major step forward (Brady and Morfini, 2010). However,
mutations in molecular motors are rare, usually embryonic
lethal, and only account for a small proportion of neurological
disorders. It has become established in recent years, that
deficiencies in AT are associated to a larger group of misfolding
diseases including AD, PD, and PrDs. And, current research
indicates that AT deficiencies observed in these diseases are
induced by altered kinases involved in regulation of AT
(Gibbs et al., 2015; Brady and Morfini, 2017). Altogether, this
molecular and pharmacological information will set the basis for
developing novel target-driven pharmacological interventions
specific for each disease. These interventions will in turn
ameliorate neuronal AT and therefore prevent or slow down
the dying back progression of axonal degeneration and loss
(Brady and Morfini, 2017).
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